Bristol-Myers Squibb’s first quarter results reflected a blend of strong execution in its newer growth portfolio and ongoing ...

From a price-performance perspective, PFE has performed better than BMY so far this year. Shares of PFE have declined 6.8%, ...

Introduction A major driver of the global autologous cell therapy market is the rising demand for personalized and precision-based medical trea ...

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers sparked headlines with impressive new data for Breyanzi, its cancer therapy targeting relapsed marginal zone ...

Retail investor chatter around Bristol Myers Squibb intensified on Monday following the release of new clinical data, which ...